BTAI
Bioxcel Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 5
Bearish signal 3
Stock Price Surged Significantly
Consensus Rating "Strong Buy"
High Gross Profit Margin
Significant Net Income Decline
Revenue Beats Expectation
EPS Beats Expectation
Price Hits New Low
Price Hits 52-week Low
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About BTAI
Bioxcel Therapeutics, Inc.
A biopharmaceutical company developing novel therapeutics for neuroscience and immuno-oncology disorders
Pharmaceutical
03/29/2017
03/08/2018
NASDAQ Stock Exchange
37
12-31
Common stock
555 Long Wharf Drive, New Haven, CT 06511
--
Bioxcel Therapeutics, Inc., a Delaware corporation, was incorporated on March 29, 2017 and is a wholly-owned subsidiary of BioXcel. BioXcel Therapeutics, Inc., or BTI, is a clinical-stage biopharmaceutical company focused on drug development, using novel artificial intelligence or artificial intelligence to identify the next wave of drugs in neuroscience and immuno-oncology. The company's drug re-innovation approach utilizes existing approved drugs or clinically proven product candidates as well as big data and proprietary machine learning algorithms to identify new therapeutic metrics. The Company's two most advanced clinical development programs are BXCL501, a sublingual membrane formulation of the a2a adrenergic receptor agonist dexmedetomidine or Dex for the acute treatment of agitation caused by neurological and psychiatric diseases, and BXCL701, a sublingual membrane formulation for the treatment of rare forms of prostate and pancreatic cancer. The company started a Phase 1 b pharmacokinetic/pharmacodynamic safety study with Dex's IV formulation in mild probable AD or PK/PD in December 2017, and the company plans to start a Phase 1 b pharmacokinetic/pharmacodynamic safety study with Dex's IV formulation in patients with schizophrenia, and the company expects to report data from both studies in the second half of 2018. The company also intends to start Phase 2 proof-of-concept or PoC open-label clinical trials for two programs in 2018.
Company Financials
EPS
BTAI has released its 2025 Q3 earnings. EPS was reported at -2.18, versus the expected -1.34, missing expectations. The chart below visualizes how BTAI has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
BTAI has released its 2025 Q3 earnings report, with revenue of 98.00K, reflecting a YoY change of -54.21%, and net profit of -30.91M, showing a YoY change of -126.45%. The Sankey diagram below clearly presents BTAI's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
